Investigating a series of seven cell lines and 27 PDX samples, our study did not reveal significant differences in the efficacy of the three inhibitors for cell death induction in BCP-ALL, emphasizing the relevance of BCL-XL and MCL-1 as therapeutic targets in addition to BCL-2. This evidence concerns the gene MCL1 and acute lymphoblastic leukemia.